Procaps Group (Procaps Group) FCF Margin % : 33.54% (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Procaps Group FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Procaps Group's Free Cash Flow for the three months ended in Sep. 2023 was $39.7 Mil. Procaps Group's Revenue for the three months ended in Sep. 2023 was $118.4 Mil. Therefore, Procaps Group's FCF Margin % for the quarter that ended in Sep. 2023 was 33.54%.

As of today, Procaps Group's current FCF Yield % is 11.61%.

The historical rank and industry rank for Procaps Group's FCF Margin % or its related term are showing as below:

PROC' s FCF Margin % Range Over the Past 10 Years
Min: -4.26 Med: 9.04 Max: 15.99
Current: 8.23

During the past 4 years, the highest FCF Margin % of Procaps Group was 15.99%. The lowest was -4.26%. And the median was 9.04%.

PROC's FCF Margin % is ranked better than
72.28% of 1021 companies
in the Drug Manufacturers industry
Industry Median: 0.25 vs PROC: 8.23

Procaps Group FCF Margin % Historical Data

The historical data trend for Procaps Group's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Procaps Group FCF Margin % Chart

Procaps Group Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

FCF Margin %

14.96

15.99

3.12

-4.26

Procaps Group Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
FCF Margin %	Get a 7-Day Free Trial											-1.51	-16.23	-2.09	11.42	33.54

Competitive Comparison of Procaps Group's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Procaps Group's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Procaps Group's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Procaps Group's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Procaps Group's FCF Margin % falls into.

Procaps Group FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Procaps Group's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-17.469	/	409.92
	=	-4.26 %

Procaps Group's FCF Margin for the quarter that ended in Sep. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	39.714	/	118.41
	=	33.54 %

Procaps Group FCF Margin % Related Terms

Thank you for viewing the detailed overview of Procaps Group's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Procaps Group (Procaps Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Procaps Group SA (NAS:PROC) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

9X1:Germany

Address

9 Rue de Bitbourg, Luxembourg, LUX, L-1273

Website

https://www.procapsgroup.com

Procaps Group SA is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. It develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements, and high-potency clinical solutions. The company's segment includes NextGel; Procaps Colombia; CAN; CASAND and Diabetrics. It generates maximum revenue from the Procaps Colombia segment.

Executives

Alexandre Weinstein Manieu	director, 10 percent owner	CHASHAM PLACE, FLAT 1, LONDON X0 SW1X 8HG
Ruben Minski	director, 10 percent owner, officer: Chief Executive Officer	9 RUE DE BITBOURG, C/O PROCAPS GROUP, S.A., LUXEMBOURG N4 L-1273
Jose Minski	director, 10 percent owner	9 RUE DE BITBOURG, C/O PROCAPS GROUP, S.A., LUXEMBOURG N4 L-1273
Sognatore Trust	10 percent owner	OFICINA 503A-02, EDIFICIO QUANTUM, (500) RUTA 8 KM. 17.500 ZONAMERICA, MONTEVIDEO X3 91600
Simphony Trust	10 percent owner	29 BANCROFT MILLS ROAD, WILMINGTON DE 19806
Deseja Trust	10 percent owner	29 BANCROFT MILLS ROAD, WILMINGTON DE 19806
Hoche Partners Pharma Holding S.a.	10 percent owner	3A VAL SAINTE CROIX, LUXEMBOURG N4 L-1371